- Two Species or Not Two Species? New Data to Re-evaluate Toxicology Testing Strategies Across the Sectors
-
Room 303‚ Convention Center
Chair: Fiona Sewell, National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs), United Kingdom
Co-Chair: Ruth Roberts, ApconiX, United Kingdom
Primary Endorser: Regulatory and Safety Evaluation Specialty Section
Endorser(s): Risk Assessment Specialty SectionRegulatory toxicology is ready for change. For decades, safety assessment of pharmaceuticals, chemicals and agrochemicals has defaulted to testing in two species (both a rodent and a non-rodent) with the aim of identifying human health risks that might be missed if relying on a single species alone. While this two species paradigm was established to increase confidence in risk identification, its scientific justification and added value are under increasing scrutiny, particularly for non rodents such as dogs and non-human primates. Accumulating evidence based on retrospective and prospective analyses has driven renewed momentum to explore whether there are opportunities where testing in a single, appropriately selected species could be sufficient to support human safety decisions. A clear precedent for regulatory evolution exists in the agrochemical sector. Prior to 2007, a one-year dog study was routinely required. However, a comprehensive retrospective analysis of more than 100 compounds demonstrated that this dog study rarely provided additional toxicological insights beyond those obtained from the subchronic (90-day) dog study. This evidence prompted an update of the Organisation for Economic Co-operation and Development (OECD) Test Guidelines, shifting the one-year dog study from a mandatory requirement to a case-by-case request, without comprising human health protection. Similar discussions are ongoing in the pharmaceutical sector. Although general guidelines (i.e. ICH M3(R2)) still require toxicity testing in two species, flexibility exists for biologics under ICH S6(R1). In this context, single species approaches are accepted when there is only one pharmacologically relevant species, and for chronic toxicity studies, when earlier findings are similar across species or the mechanism of action is well characterized. Consequently, regulators are increasingly accepting single species toxicology packages for biologics when supported by robust scientific justification, and there is growing interest in identifying opportunities to waive the second species requirement in other well defined scenarios. At the same time, new approach methodologies (NAMs) have been rapidly evolving and are poised to play a key role in enhancing safety assessments. These approaches complement and enrich in vivo data, and can provide evidence to support confidence in single-species testing strategies. This session will showcase current projects from different sectors, aiming to reshape our practice. Speakers will present: (1) a perspective by the United States Environmental Protection Agency (US EPA), comparing recent retrospective analyses on the value of subchronic dog studies, to contextualize areas of concordance and divergence; (2) Results from a recent industry retrospective analysis challenging the necessity of the 90 day dog study in agrochemical safety assessment; (3) New evidence from a multi company data sharing initiative revealing opportunities where a single species may be sufficient in later-development studies for small molecule pharmaceuticals; and (4) Progress on the CRACK IT Virtual Second Species (VSS) suite 'DigiDog', combining machine learning, mechanistic modelling and toxicology data to predict non rodent outcomes. The DigiDog aims to reduce reliance on, or replace, chronic dog studies with a virtual dog across the sectors. Together, these talks provide a timely, evidence-driven view of how second species requirements could be modernized across sectors while enhancing human safety, scientific rigor and the 3Rs. This session will be of interest to academics, industry, contract research organizations and regulators, all of whom share a 3Rs goal.
Session and Activity Type
Enter Note
Go to previous page in this tab
Event
